ALK-Positive Large B-Cell Lymphoma

Details 216 Trials 16 Therapies

A usually aggressive large B-cell lymphoma characterized by the presence of monomorphic immunoblast-like neoplastic B-lymphocytes in a sinusoidal growth pattern. The neoplastic B-lymphocytes express the ALK kinase but they lack the 2;5 translocation.

parent conditions

Diffuse Large B-Cell Lymphoma

synonyms

ALK-DLBCL

ALK-Positive Large B-Cell Lymphoma

ALK Positive Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma with Expression of Full-Length ALK

Diffuse Large B-Cell Lymphoma with Expression of Full-Length Anaplastic Lymphoma Kinase

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

281 sites for NCT04824092

ALK Fusion, +4 more biomarkers

ALK-Positive Large B-Cell Lymphoma, +7 more conditions

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

222 sites for NCT04529772

IRF4 Expression, +1 more biomarker

Diffuse Large B-Cell Lymphoma

acalabrutinib, +5 more drugs

chemotherapy, +3 more types

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

97 sites for NCT04404283

Diffuse Large B-Cell Lymphoma, +1 more condition

brentuximab vedotin, +2 more drugs

chemotherapy, +1 more type

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

205 sites for NCT02443077

IRF4 Expression, +1 more biomarker

Diffuse Large B-Cell Lymphoma, +1 more condition

autologous hematopoietic stem cell transplantation, +6 more drugs

cellular therapy, +2 more types

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

3 sites for NCT05139017

Diffuse Large B-Cell Lymphoma

bendamustine, +4 more drugs

chemotherapy, +2 more types

A Phase 3 Trial of Epcoritamab in R/R DLBCL

97 sites for NCT04628494

BCL2 Fusion, +3 more biomarkers

Diffuse Large B-Cell Lymphoma, +5 more conditions

epcoritamab

immunotherapy

Show 216 Trials for ALK-Positive Large B-Cell Lymphoma

rituximab + chemotherapy